{"id":"NCT00969436","sponsor":"GlaxoSmithKline","briefTitle":"Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM","officialTitle":"A Phase IIIb, Open, Randomised, Multicentre, Primary Study in Healthy Children, to Establish the Non-inferiority of GlaxoSmithKline (GSK) Biologicals' MeMuRu-OKA Vaccine (Administered at 9 and 15 Months of Age) Versus Priorix™ (9 Months of Age) and Priorix™ Co-administered With Varilrix™ at 15 Months of Age (Comparator) and Also to Evaluate the Non-inferiority of Priorix™ (9 Months of Age) and MeMuRu-OKA Vaccine (15 Months of Age) Versus the Comparator, All Administered Subcutaneously as Two-dose Primary Vaccination Course","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11-09","primaryCompletion":"2011-02-21","completion":"2011-02-21","firstPosted":"2009-09-01","resultsPosted":"2017-09-25","lastUpdate":"2018-06-08"},"enrollment":450,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Varicella","Rubella","Mumps","Measles"],"interventions":[{"type":"BIOLOGICAL","name":"GSK Biological's investigational MMRV vaccine 208136","otherNames":[]},{"type":"BIOLOGICAL","name":"Priorix™","otherNames":[]},{"type":"BIOLOGICAL","name":"Varilrix™","otherNames":[]}],"arms":[{"label":"Priorix-Tetra Group","type":"EXPERIMENTAL"},{"label":"Priorix/ Priorix-Tetra Group","type":"EXPERIMENTAL"},{"label":"Control Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess non-inferiority of two different vaccination regimens using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorix™ (9 months) and one dose of MMRV vaccine (15 months) to the current standard of care which is Priorix™ administered at 9 months of age followed by concomitant administration of Priorix™ with Varilrix™ at 15 months of age in a measles endemic environment such as India.","primaryOutcome":{"measure":"Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Antibodies","timeFrame":"At 42 - 56 days after the second vaccination dose at week 30","effectByArm":[{"arm":"Priorix-Tetra Group","deltaMin":149,"sd":null},{"arm":"Priorix/ Priorix-Tetra Group","deltaMin":153,"sd":null},{"arm":"Control Group","deltaMin":72,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"9 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":6,"countries":["India"]},"refs":{"pmids":["26362659"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":180},"commonTop":["Fever; Dose 1","Fever; Dose 2","Pain; Dose 1","Redness; Dose 1","Cough; Dose 1"]}}